Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taselisib + Fulvestrant in Advanced Breast Cancer
NCT02340221Phase 3Terminated
- Sponsor
- Roche
- Start
- Apr 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of taselisib / pictilisib in breast cancer, sponsored by Roche. Started Apr 2015; status: terminated.
02
Drugs
taselisib / pictilisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02340221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340221.